$MYSZ
My Size, Inc. Stock $mysz

$mysz Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224012542 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$2.984M	$2.830M	$6.996M
YoY Change	314.44%	11.86%	56.9%
Cost Of Revenue	$1.788M	$1.567M	$4.265M
YoY Change	55.88%	-29.41%	11.5%
Gross Profit	$1.196M	$1.263M	$2.731M
YoY Change	-380.09%	307.42%	330.76%
Gross Profit Margin	40.08%	44.63%	39.04%
Selling, General & Admin	$2.135M	$2.019M	$7.827M
YoY Change	23.91%	-5.65%	11.13%
% of Gross Profit	178.51%	159.86%	286.6%
Research & Development	$132.0K	$163.0K	$974.0K
YoY Change	-61.4%	-70.36%	-42.74%
% of Gross Profit	11.04%	12.91%	35.66%
Depreciation & Amortization	$8.000K	$76.00K	$329.0K
YoY Change	-70.37%	8.57%	765.79%
% of Gross Profit	0.67%	6.02%	12.05%
Operating Expenses	$2.267M	$2.182M	$8.801M
YoY Change	9.78%	-18.88%	0.65%
Operating Profit	-$1.071M	-$919.0K	-$6.070M
YoY Change	-57.02%	-61.39%	-25.15%
Interest Expense	$55.00K	$154.0K	$28.00K
YoY Change	-130.56%	-485.0%	-111.67%
% of Operating Profit
Other Income/Expense, Net	$55.00K		$99.00K
YoY Change	-137.67%		-141.95%
Pretax Income	-$1.016M	-$1.436M	-$6.713M
YoY Change	-61.98%	-40.66%	-19.57%
Income Tax		-$133.0K	-$333.0K
% Of Pretax Income
Net Earnings	-$1.016M	-$1.303M	-$6.380M
YoY Change	-61.72%	-45.25%	-23.23%
Net Earnings / Revenue	-34.05%	-46.04%	-91.19%
Basic Earnings Per Share	-$1.88		-$2.50
Diluted Earnings Per Share	-$1.88	-$3.20	-$20.01
COMMON SHARES
Basic Shares Outstanding	5.092M shares	2.982M shares	2.551M shares
Diluted Shares Outstanding	539.0K shares		2.551M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.136M	$2.187M	$2.187M
YoY Change	-53.06%	1.86%	4.14%
Cash & Equivalents	$1.136M	$2.187M	$2.187M
Short-Term Investments		$6.000K
Other Short-Term Assets	$75.00K	$99.00K	$164.0K
YoY Change	-71.15%	-61.92%	-36.92%
Inventory	$2.136M	$2.879M	$2.879M
Prepaid Expenses		$65.00K
Receivables	$406.0K	$615.0K	$615.0K
Other Receivables	$1.001M	$847.0K	$782.0K
Total Short-Term Assets	$4.754M	$6.627M	$6.627M
YoY Change	-4.02%	9.39%	9.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$113.0K	$472.0K	$472.0K
YoY Change	5.61%	237.14%	-34.44%
Goodwill	$741.0K	$758.0K
YoY Change	-47.52%	-45.66%
Intangibles	$996.0K	$1.097M
YoY Change	-24.14%	-20.33%
Long-Term Investments	$11.00K	$30.00K	$30.00K
YoY Change	-89.0%	-80.0%	-80.0%
Other Assets	$7.000K	$7.000K	$7.000K
YoY Change	-76.67%	-76.67%	-76.67%
Total Long-Term Assets	$1.916M	$2.364M	$2.364M
YoY Change	-45.49%	-35.57%	-35.59%
TOTAL ASSETS
Total Short-Term Assets	$4.754M	$6.627M	$6.627M
Total Long-Term Assets	$1.916M	$2.364M	$2.364M
Total Assets	$6.670M	$8.991M	$8.991M
YoY Change	-21.23%	-7.57%	-7.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.114M	$2.154M	$2.154M
YoY Change	-37.06%	-13.49%	-13.49%
Accrued Expenses	$53.00K	$158.0K	$158.0K
YoY Change	-66.88%	-1.25%	-1.25%
Deferred Revenue
YoY Change
Short-Term Debt	$582.0K	$158.0K	$158.0K
YoY Change	268.35%	1.94%	-1.25%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.699M	$3.878M	$3.878M
YoY Change	-5.33%	-7.2%	-7.22%
LONG-TERM LIABILITIES
Long-Term Debt	$218.0K	$249.0K	$249.0K
YoY Change	-36.26%	-33.78%	-34.47%
Other Long-Term Liabilities	$0.00	$129.0K	$129.0K
YoY Change	-100.0%	-58.39%	-58.39%
Total Long-Term Liabilities	$218.0K	$378.0K	$378.0K
YoY Change	-77.17%	-62.65%	-45.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.699M	$3.878M	$3.878M
Total Long-Term Liabilities	$218.0K	$378.0K	$378.0K
Total Liabilities	$2.917M	$4.256M	$4.256M
YoY Change	-23.36%	-18.01%	-18.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$60.90M	-$59.88M
YoY Change	8.44%	11.93%
Common Stock	$1.000K	$4.000K
YoY Change	-50.0%	300.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.753M	$4.735M	$4.735M
YoY Change
Total Liabilities & Shareholders Equity	$6.670M	$8.991M	$8.991M
YoY Change	-21.23%	-7.57%	-7.6%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.016M	-$1.303M	-$6.380M
YoY Change	-61.72%	-45.25%	-23.23%
Depreciation, Depletion And Amortization	$8.000K	$76.00K	$329.0K
YoY Change	-70.37%	8.57%	765.79%
Cash From Operating Activities	-$1.417M	-$1.196M	-$6.106M
YoY Change	-38.74%	-16.36%	-16.24%
INVESTING ACTIVITIES
Capital Expenditures		$7.000K	$7.000K
YoY Change			-74.07%
Acquisitions
YoY Change
Other Investing Activities	$60.00K
YoY Change
Cash From Investing Activities	$60.00K	-$7.000K	-$7.000K
YoY Change		-98.94%	-99.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.258M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$407.0K	-96.00K	6.134M
YoY Change	-84.55%	220.0%	-9255.22%
NET CHANGE
Cash From Operating Activities	-$1.417M	-1.196M	-6.106M
Cash From Investing Activities	$60.00K	-7.000K	-7.000K
Cash From Financing Activities	$407.0K	-96.00K	6.134M
Net Change In Cash	-$1.053M	-1.299M	21.00K
YoY Change	-436.42%	-38.73%	-100.24%
FREE CASH FLOW
Cash From Operating Activities	-$1.417M	-$1.196M	-$6.106M
Capital Expenditures		$7.000K	$7.000K
Free Cash Flow		-$1.203M	-$6.113M
YoY Change		-15.87%	-16.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001211805
CY2022Q4	MYSZ	Sort Term Deposit SortTermDeposit		usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022	MYSZ	Stock Issued During Period Value Effect Of Reverse Stock Splits StockIssuedDuringPeriodValueEffectOfReverseStockSplits		usd
CY2022	MYSZ	Increase Decrease In Investment In Joint Venture IncreaseDecreaseInInvestmentInJointVenture		usd
CY2022	MYSZ	Increase Decrease In Deferred Tax Liabilities IncreaseDecreaseInDeferredTaxLiabilities		usd
CY2023	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates		usd
CY2023	MYSZ	Payment Of Investing In Other Receivable PaymentOfInvestingInOtherReceivable		usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments		usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022Q4	MYSZ	Prepaid Loan PrepaidLoan		usd
CY2023Q4	MYSZ	Lessee Operating Lease Liability Payments Due After Year Two LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo		usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross		usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022	MYSZ	Finite Lived Intangible Assets Amortization Translation Gain Loss FiniteLivedIntangibleAssetsAmortizationTranslationGainLoss		usd
CY2021Q4	us-gaap	Goodwill Goodwill		usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	847000	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	MYSZ	Income Tax Reconciliation Exchange Tax Rate Differential IncomeTaxReconciliationExchangeTaxRateDifferential		usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	MYSZ	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	MYSZ	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	MYSZ	Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	MYSZ	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents		usd
CY2022	us-gaap	Unrealized Gain On Foreign Currency Derivatives Before Tax UnrealizedGainOnForeignCurrencyDerivativesBeforeTax		usd
CY2023	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax		usd
CY2023	MYSZ	Revaluation Of Loan Granted RevaluationOfLoanGranted		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-37370
CY2023	dei	Entity Registrant Name EntityRegistrantName	MY SIZE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	51-0394637
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4 Hayarden
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	POB 1026
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Airport City
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	7010000
CY2023	dei	City Area Code CityAreaCode	972
CY2023	dei	Local Phone Number LocalPhoneNumber	3- 6009030
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	MYSZ
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2360756	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5091668	shares
CY2023	dei	Auditor Firm AuditorFirmId	1057
CY2023	dei	Auditor Name AuditorName	Somekh Chaikin
CY2023	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2187000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2100000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	77000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	263000	usd
CY2023Q4	MYSZ	Sort Term Deposit SortTermDeposit	22000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2879000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	997000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	615000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1940000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	758000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6627000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6058000	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	7000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	28000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	121000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	140000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	351000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	583000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1097000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1377000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	758000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1395000	usd
CY2023Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	24000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	99000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	6000	usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	47000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2364000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3669000	usd
CY2023Q4	us-gaap	Assets Assets	8991000	usd
CY2022Q4	us-gaap	Assets Assets	9727000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	158000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	159000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	158000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	155000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2154000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2487000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	605000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	698000	usd
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	803000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	680000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3878000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4179000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	249000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	376000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	328000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	308000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	378000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1012000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4256000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5191000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3621792	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3621792	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1464117	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1464117	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	65383000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	58673000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-771000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-637000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59881000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53501000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4735000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4536000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8991000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9727000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6996000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4459000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	4265000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3825000	usd
CY2023	us-gaap	Gross Profit GrossProfit	2731000	usd
CY2022	us-gaap	Gross Profit GrossProfit	634000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3856000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3971000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3900000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	671000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9472000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	8744000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8110000	usd
CY2023	MYSZ	Equity Loss Of Equity Method Investees EquityLossOfEquityMethodInvestees	71000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6713000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8346000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-333000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-36000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6380000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8310000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-134000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax	-231000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6514000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8541000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.50
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.50
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.47
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.47
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2550779	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2550779	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1111913	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1111913	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10857000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	455000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1446000	usd
CY2022	MYSZ	Stock Issued During Period Value Acquisitions One StockIssuedDuringPeriodValueAcquisitionsOne	319000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8541000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4536000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4536000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	453000	usd
CY2023	MYSZ	Issuance Of Cost Net IssuanceOfCostNet	959000	usd
CY2023	MYSZ	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	2000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6514000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4735000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4735000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-6380000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8310000	usd
CY2023	us-gaap	Depreciation Depreciation	27000	usd
CY2022	us-gaap	Depreciation Depreciation	38000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	137000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	135000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	302000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	155000	usd
CY2023	MYSZ	Revaluation Of Warrants And Derivatives RevaluationOfWarrantsAndDerivatives	-99000	usd
CY2022	MYSZ	Revaluation Of Warrants And Derivatives RevaluationOfWarrantsAndDerivatives	-23000	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-93000	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	635000	usd
CY2023	MYSZ	Interest On Long Term Liabilities InterestOnLongTermLiabilities	57000	usd
CY2022	MYSZ	Interest On Long Term Liabilities InterestOnLongTermLiabilities	10000	usd
CY2023	us-gaap	Interest Paid InterestPaid	23000	usd
CY2022	us-gaap	Interest Paid InterestPaid	10000	usd
CY2023	MYSZ	Revaluation Of Investment In Marketable Securities RevaluationOfInvestmentInMarketableSecurities	-41000	usd
CY2022	MYSZ	Revaluation Of Investment In Marketable Securities RevaluationOfInvestmentInMarketableSecurities	-62000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-328000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-36000	usd
CY2023	MYSZ	Increase Decrease In Investment In Joint Venture IncreaseDecreaseInInvestmentInJointVenture	71000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	453000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	774000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1839000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	219000	usd
CY2023	MYSZ	Increase Decrease In Deferred Tax Liabilities IncreaseDecreaseInDeferredTaxLiabilities	-671000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1200000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1863000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-115000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-142000	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	84000	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-184000	usd
CY2023	MYSZ	Increase Decrease In Trade Payable IncreaseDecreaseInTradePayable	-306000	usd
CY2022	MYSZ	Increase Decrease In Trade Payable IncreaseDecreaseInTradePayable	1315000	usd
CY2023	MYSZ	Increase Decrease In Other Payables IncreaseDecreaseInOtherPayables	202000	usd
CY2022	MYSZ	Increase Decrease In Other Payables IncreaseDecreaseInOtherPayables	5000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6106000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7290000	usd
CY2022	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	767000	usd
CY2022	MYSZ	Payment Of Investing In Other Receivable PaymentOfInvestingInOtherReceivable	100000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	99000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-993000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6258000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	124000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	67000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6134000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-67000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-120000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-230000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-99000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8580000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2363000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	10943000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2264000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2363000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-59881000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zkSVAG11jS25" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. <span><span id="xdx_862_z0CpIxiyHw1b">Use of estimates</span>:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information about assumptions made by the Company with respect to the future and other reasons for uncertainty with respect to estimates that have a significant risk of resulting in a material adjustment to carrying amounts of assets and liabilities in the next financial year are included in the following units reporting:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Estimated impairment of non-financial assets</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company examines on an annual basis whether there is an impairment of goodwill, intangibles and property, plant and equipment that are allocated to reporting units, in accordance with the accounting policy presented in Note 1 (h) below. The fair value calculations of reporting units require the use of estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For information on key assumptions used in calculation of the fair value, see NOTE 7 – Goodwill and other Intangible assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	39	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	671000	usd
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.0833	pure
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	measure the tax benefit as the largest amount that is greater than 50 percent (cumulative basis) likely to be realized upon settlement.
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zOjgpViuW8e2" style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_862_zKTRSS7kaHvf">Concentrations of credit risk</span>:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company and its subsidiaries to concentrations of credit risk consist principally of cash and cash equivalents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are invested in banks in Israel, Spain and United States. Such deposits in Israel may be in excess of insured limits and are not insured in other jurisdictions. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and its subsidiaries have no off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MY SIZE, INC. AND ITS SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>U.S. dollars in thousands (except share data and per share data)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES (Cont.)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	MYSZ	Allowance For Sales Returns AllowanceForSalesReturns	260000	usd
CY2023Q4	us-gaap	Contract With Customer Refund Liability ContractWithCustomerRefundLiability	260000	usd
CY2022Q4	us-gaap	Contract With Customer Refund Liability ContractWithCustomerRefundLiability	161000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2187000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2100000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	65000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	322000	usd
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	511000	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	283000	usd
CY2023Q4	MYSZ	Prepaid Loan PrepaidLoan	75000	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	196000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	153000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	847000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	758000	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	9	pure
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	334000	usd
CY2022	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	27000	usd
CY2022	MYSZ	Property Plant And Equipment Business Combination PropertyPlantAndEquipmentBusinessCombination	55000	usd
CY2022	MYSZ	Property Plant And Equipment Translations Adjustments PropertyPlantAndEquipmentTranslationsAdjustments	-4000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	368000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	368000	usd
CY2023	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	7000	usd
CY2023	MYSZ	Property Plant And Equipment Translations Adjustments PropertyPlantAndEquipmentTranslationsAdjustments	-4000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	371000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	222000	usd
CY2022	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	38000	usd
CY2022	MYSZ	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease Translations Adjustments AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecreaseTranslationsAdjustments	-32000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	228000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	228000	usd
CY2023	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	27000	usd
CY2023	MYSZ	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease Translations Adjustments AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecreaseTranslationsAdjustments	-5000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	250000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	140000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	121000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	351000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	158000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.1195	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	206000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	141000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	60000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	287000	usd
CY2022	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	1467000	usd
CY2022	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	65000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1532000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1532000	usd
CY2023	us-gaap	Finite Lived Intangible Assets Foreign Currency Translation Gain Loss FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	24000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1556000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1556000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	155000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-155000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-155000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	302000	usd
CY2023	MYSZ	Finite Lived Intangible Assets Amortization Translation Gain Loss FiniteLivedIntangibleAssetsAmortizationTranslationGainLoss	-2000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-459000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-459000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1377000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1097000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1097000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	302000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	155000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	288000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	186000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	176000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	176000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	119000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	152000	usd
CY2023Q4	MYSZ	Finite Lived Intangible Asset Net FiniteLivedIntangibleAssetNet	1097000	usd
CY2022	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1304000	usd
CY2022	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	91000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1395000	usd
CY2023	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	34000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	671000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	758000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	671000	usd
CY2023Q3	MYSZ	Ownership Percentage On Joint Venture OwnershipPercentageOnJointVenture	0.51	pure
CY2023	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	71000	usd
CY2022	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	0	usd
CY2023	MYSZ	Schedule Of Financial Liability Maturities Table Text Block. ScheduleOfFinancialLiabilityMaturitiesTableTextBlock.	<p id="xdx_893_ecustom--ScheduleOfFinancialLiabilityMaturitiesTableTextBlock._ztCikctw724b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial liability maturities during the five years following the end of the financial year are shown below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zCrgSZejA8re" style="display: none">SCHEDULE OF FINANCIAL LIABILITY MATURITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" style="font-weight: bold; text-align: center"><b>Until</b></td><td style="text-align: center; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" style="font-weight: bold; text-align: center"><b>Until</b></td><td style="text-align: center; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" style="font-weight: bold; text-align: center"><b>Until</b></td><td style="text-align: center; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" style="font-weight: bold; text-align: center"><b>Until</b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" style="font-weight: bold; text-align: center"><b>Until</b></td><td style="text-align: center; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold"><b> </b></td> <td colspan="2" style="font-weight: bold; text-align: center"><b>TOTAL</b></td><td style="text-align: center; font-weight: bold"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>31-12-24</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>31-12-25</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>31-12-26</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>31-12-27</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td> <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>31-12-28</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>31-12-23</b></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td> <td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Debts with credit institutions</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--DebtsWithCreditInstitutionsMember_zvNQNso1ynt6" style="width: 5%; text-align: right" title="Until 3-12-24"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">158</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--DebtsWithCreditInstitutionsMember_zoWDPFTKiftg" style="width: 5%; text-align: right" title="Until 3-12-25"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--DebtsWithCreditInstitutionsMember_zHnp4ViNhge" style="width: 5%; text-align: right" title="Until 3-12-26">90</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--DebtsWithCreditInstitutionsMember_zBJNENgDJmqb" style="width: 5%; text-align: right" title="Until 3-12-27">50</td><td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--DebtsWithCreditInstitutionsMember_zoPjf8hYjv25" style="width: 5%; text-align: right" title="Until 31-12-28">14</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--LongTermDebt_iI_c20231231__us-gaap--FinancialInstrumentAxis__custom--DebtsWithCreditInstitutionsMember_zoM3dQ4wels6" style="width: 5%; text-align: right" title="TOTAL">407</td><td style="width: 1%; text-align: left"> </td></tr> </table>
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	605000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	698000	usd
CY2023	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1707000	usd
CY2022	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2952000	usd
CY2023	MYSZ	Marketable Securities Loss MarketableSecuritiesLoss	41000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	6000	usd
CY2022	MYSZ	Marketable Securities Loss MarketableSecuritiesLoss	59000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	47000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	27037000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	27037000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	16488000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	10585000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2375000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-1180000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-4338000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7166000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6713000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8346000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21172000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20131000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	102000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	145000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	419000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	390000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	226000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	586000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	16000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	203000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21935000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21455000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21663000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21455000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	272000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	272000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	328000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	328000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21455000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21082000	usd
CY2023	MYSZ	Deferred Tax Assets Valuation Allowance Additions In Income Statement DeferredTaxAssetsValuationAllowanceAdditionsInIncomeStatement	988000	usd
CY2022	MYSZ	Deferred Tax Assets Valuation Allowance Additions In Income Statement DeferredTaxAssetsValuationAllowanceAdditionsInIncomeStatement	1758000	usd
CY2023	MYSZ	Additions In Valuation Allowance Due To Exchange Rate Foreign Currency Translation Differences AdditionsInValuationAllowanceDueToExchangeRateForeignCurrencyTranslationDifferences	-780000	usd
CY2022	MYSZ	Additions In Valuation Allowance Due To Exchange Rate Foreign Currency Translation Differences AdditionsInValuationAllowanceDueToExchangeRateForeignCurrencyTranslationDifferences	-1385000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	208000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	373000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21663000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21455000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6713000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8346000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-1410000	usd
CY2022	us-gaap	Other Tax Expense Benefit OtherTaxExpenseBenefit	-1752000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-73000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-149000	usd
CY2023	MYSZ	Income Tax Reconciliation Exchange Tax Rate Differential IncomeTaxReconciliationExchangeTaxRateDifferential	-47000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	41000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	107000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	168000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	988000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1758000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-333000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-36000	usd
CY2022Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-25 reverse stock split of the Company’s issued and outstanding shares of common stock.
CY2023Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4200000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	287964	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	31.00
CY2021	MYSZ	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P4Y4M6D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	17901	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	270063	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.21
CY2022	MYSZ	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y4M9D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	8641803	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	3067572	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5844294	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.41
CY2023	MYSZ	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P3Y9M
CY2023Q4	MYSZ	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	5844294	shares
CY2023Q4	MYSZ	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercisable ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisable	3.41
CY2023	MYSZ	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm	P3Y9M
CY2023	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	453000	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	774000	usd
CY2023	MYSZ	Share Based Compensation Arrangement By Share Based Payment Award Options Options For Common Stock ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionsForCommonStock	5488	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1488	shares
CY2023Q3	MYSZ	Incremental Compensation Cost IncrementalCompensationCost	10000	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	371000	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	455000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	153000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	364000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	55000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	864000	usd
CY2022Q4	MYSZ	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Long Term Financial Investment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermFinancialInvestment	31000	usd
CY2022Q4	MYSZ	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Selling Platform BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSellingPlatform	378000	usd
CY2022Q4	MYSZ	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill	152000	usd
CY2022Q4	MYSZ	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Short Term Credit BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedShortTermCredit	181000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	668000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	13000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt	138000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities	87000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	757000	usd
CY2023Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	0	usd
CY2022Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	40000	usd
CY2023	MYSZ	Additional Cash Consideration AdditionalCashConsideration	130000	usd
CY2022	MYSZ	Additional Cash Consideration AdditionalCashConsideration	283000	usd
CY2023	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	125	usd
CY2023Q4	us-gaap	Noncurrent Assets NoncurrentAssets	2351000	usd
CY2022Q4	us-gaap	Noncurrent Assets NoncurrentAssets	3594000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3856000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3143000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3971000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3900000	usd
CY2023	us-gaap	Unrealized Gain On Foreign Currency Derivatives Before Tax UnrealizedGainOnForeignCurrencyDerivativesBeforeTax	99000	usd
CY2023	us-gaap	Other Income OtherIncome	97000	usd
CY2022	us-gaap	Other Income OtherIncome	26000	usd
CY2023	MYSZ	Financial Income FinancialIncome	196000	usd
CY2022	MYSZ	Financial Income FinancialIncome	26000	usd
CY2022	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	33000	usd
CY2022	MYSZ	Revaluation Of Loan Granted RevaluationOfLoanGranted	100000	usd
CY2023	MYSZ	Revaluation Investment In Marketable Securities RevaluationInvestmentInMarketableSecurities	41000	usd
CY2022	MYSZ	Revaluation Investment In Marketable Securities RevaluationInvestmentInMarketableSecurities	62000	usd
CY2023	us-gaap	Other Expenses OtherExpenses	56000	usd
CY2022	us-gaap	Other Expenses OtherExpenses	67000	usd
CY2023	MYSZ	Financial Expense FinancialExpense	97000	usd
CY2022	MYSZ	Financial Expense FinancialExpense	262000	usd
CY2023Q4	us-gaap	Sale Of Stock Description Of Transaction SaleOfStockDescriptionOfTransaction	The Notification Letter provides that the Company has 180 calendar days, or until May 1, 2024, to regain compliance with the Rule. To regain compliance, the bid price of our common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. In the event we do not regain compliance by July 5, 2022, the Company may then be eligible for additional 180 days if the Company meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of the Company’s intention to cure the deficiency during the second compliance period.
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1000.00
CY2023Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-012542-index-headers.html	Edgar Link	pending
0001493152-24-012542-index.html	Edgar Link	pending
0001493152-24-012542.txt	Edgar Link	pending
0001493152-24-012542-xbrl.zip	Edgar Link	pending
ex10-31.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
mysz-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
mysz-20231231_def.xml	Edgar Link	unprocessable
mysz-20231231_lab.xml	Edgar Link	unprocessable
mysz-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mysz-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MYSZ
My Size, Inc. Stock $mysz

2024 Q1 Form 10-K Financial Statement

#000149315224012542 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYSZ My Size, Inc. Stock $mysz

2024 Q1 Form 10-K Financial Statement

#000149315224012542 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MYSZ
My Size, Inc. Stock $mysz